Concert Pharmaceuticals to Present at Upcoming Investor Conferences

On September 3, 2021 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported that it will participate virtually at the following upcoming investor conferences (Press release, Concert Pharmaceuticals, SEP 3, 2021, View Source [SID1234587220]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, on-demand beginning at 7:00 a.m. ET; and
The Cantor Virtual Global Healthcare Conference on September 30, 2021 at 3:20 p.m. ET.
Webcasts of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the conference webcasts will be available on Concert’s website for two weeks following the presentations.

Certara Announces Proposed Public Offering of Common Stock

On September 3, 2021 Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, reported a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (Press release, Certara, SEP 3, 2021, View Source [SID1234587219]). Certara is offering 4,500,000 shares of common stock and certain selling stockholders are offering 15,500,000 shares of common stock in the offering. Additionally, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to 3,000,000 additional shares of common stock. Certara intends to use the net proceeds from shares it is selling in the offering for general corporate purposes, including acquisitions. Certara will not receive any proceeds from the sale of shares in the offering by the selling stockholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is being made through an underwriting group led by Jefferies, Morgan Stanley and BofA Securities, who are acting as lead joint book-running managers.

A registration statement on Form S-1, including a prospectus, which is preliminary and subject to completion, relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering may be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 547-6340 or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at [email protected]; or BofA Securities, Inc., NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 29255 or by email at [email protected].

BioCryst to Present at Upcoming Investor Conferences

On September 3, 2021 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present at the 2021 Virtual Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 1:20 p.m. ET and at the H.C. Wainwright 23rd Annual Global Investment Conference (virtual) (Press release, BioCryst Pharmaceuticals, SEP 3, 2021, View Source [SID1234587218]). The H.C. Wainwright presentation will be available on-demand in the Investors section of BioCryst’s website starting at 7:00 a.m. ET on Monday, September 13, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to the live audio webcast of the Wells Fargo presentation and replays of both presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

Delcath Systems to Present at Upcoming Virtual Investor Conferences

On September 2, 2021 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported it will participate in three upcoming conferences (Press release, Delcath Systems, SEP 2, 2021, View Source [SID1234595224]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021

Presentation Date and Time: On-demand beginning 9/13/2021 at 7:00 AM (ET)
Webcast: View Source
Management will also host 1×1 investor meetings during the conference.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23

Presentation Date and Time: 9/21/2021 12:25 PM (ET)
Webcast: View Source
Management will also host 1×1 investor meetings during the conference.
Cantor Fitzgerald Healthcare Conference: September 27th to 30th, 2021

Presentation Date and Time: 9/29/2021 4:40 PM (ET)
Webcast: View Source
Management will also host 1×1 investor meetings during the conference.
To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

On September 2, 2021 Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, reported that Ayala management will participate in two upcoming virtual investor conferences in September (Press release, Ayala Pharmaceuticals, SEP 2, 2021, View Source [SID1234593998]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET.
Citi’s 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021.
A webcast of the H.C. Wainwright 23rd Annual Global Investor Conference presentation may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.